UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.
You may also be interested in...
UK health minister Baroness Blackwood will introduce the new UK Medicines and Medical Devices Bill before Parliament today, just before the House of Commons goes into recess. The government wants new legislation for devices and medicines in place before the end of the Brexit transition period.
Brexit And Medtech Regulation: Sorry To Spoil The Party But Experts Say There’s A Mess Here To Clear Up
31 January 2020 is an historic day as the UK formally leaves the EU. It is an emotional day, both for those wanting to see the UK depart and those who wanted the UK to remain. But the challenges are far from over. Medtech Insight reports on some reactions from key regulatory experts.
As the UK enters the final week of its 47-year membership of the EU, UK medtech industry and commentators look ahead to the routes beyond Brexit for the UK, and a likely intense and often rocky 11 months of trade deal negotiations with EU and global partners. This article is part one of two.